{"id":46610,"date":"2026-01-06T11:35:10","date_gmt":"2026-01-06T11:35:10","guid":{"rendered":"https:\/\/quickassetsmarket.com\/index.php\/2026\/01\/06\/why-theravectys-is-reportedly-considering-hong-kong-for-public-market-debut\/"},"modified":"2026-01-06T11:35:10","modified_gmt":"2026-01-06T11:35:10","slug":"why-theravectys-is-reportedly-considering-hong-kong-for-public-market-debut","status":"publish","type":"post","link":"https:\/\/quickassetsmarket.com\/index.php\/2026\/01\/06\/why-theravectys-is-reportedly-considering-hong-kong-for-public-market-debut\/","title":{"rendered":"Why TheraVectys is reportedly considering Hong Kong for public market debut"},"content":{"rendered":"
<\/div>\n

TheraVectys SA is exploring a potential initial public offering in Hong Kong<\/a>, reported Bloomberg, citing people familiar with the matter, a move that would be unusual for a non-Chinese biotech company.<\/p>\n

The France and US-based immunotherapy firm is working with advisers on a possible share sale that could raise a few hundred million dollars. <\/p>\n

A listing could take place as soon as this year if the plans progress. <\/p>\n

The deliberations reflect changing dynamics in global biotech funding, as Hong Kong regains relevance amid stronger market conditions and rising interest in health care stocks.<\/p>\n

A shift away from traditional biotech hubs<\/h2>\n

Non-Chinese biotech firms have historically gravitated toward Europe or the US when going public, drawn by deeper capital markets and a more established investor base.<\/p>\n

Against this backdrop, Hong Kong represents a less conventional option for TheraVectys. <\/p>\n

Choosing the Asian financial hub would signal a reassessment of where growth capital can be accessed efficiently, particularly at a time when global investors are rebalancing exposure across regions.<\/p>\n

Any Hong Kong listing would underline how international biotech companies are becoming more flexible in their approach to public markets, especially as competitive pressures and funding needs evolve.<\/p>\n

Hong Kong\u2019s renewed appeal to biotech firms<\/h2>\n

Hong Kong has been working to reassert itself as a destination for biotech listings following several years of muted activity. A rebound in sector valuations and successful recent offerings have improved sentiment. <\/p>\n

According to Bloomberg, around $13 billion was raised through health care share sales in Hong Kong last year, largely from biotech initial offerings and follow-on deals.<\/p>\n

Market performance has reinforced this trend. <\/p>\n

The Hang Seng Biotech Index has surged 82% over the past 12 months, reflecting stronger investor appetite for drug developers and life sciences companies.<\/p>\n

This recovery has encouraged both issuers and advisers to revisit listing plans that may have previously seemed less viable.<\/p>\n

China\u2019s growing influence on biotech investment<\/h2>\n

China has also made rapid advancement in the biotechnology sector. <\/p>\n

Increased spending on research, faster clinical development, and a growing pool of scientific talent have narrowed the gap with Western peers.<\/p>\n

As Chinese drugmakers gain prominence, investors looking for exposure to biotech innovation are increasingly active in Hong Kong. <\/p>\n

For overseas firms like TheraVectys, this environment offers access to a broader and more diverse investor base than in the past.<\/p>\n

Company background and financial backing<\/h2>\n

TheraVectys was spun out of Institut Pasteur and focuses on developing lentiviral vectors designed to prevent and treat cancer and other diseases. <\/p>\n

The technology places the company within a competitive segment of immunotherapy, where funding requirements can be substantial as research advances.<\/p>\n

The company\u2019s backers include Tethys Invest SAS, the investment arm of L\u2019Oreal SA heiress Francoise Bettencourt Meyers and her family. <\/p>\n<\/p>\n

The post Why TheraVectys is reportedly considering Hong Kong for public market debut<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

TheraVectys SA is exploring a potential initial public offering in Hong Kong, reported Bloomberg, citing people familiar with the matter, a move that would be unusual for a non-Chinese biotech company. The France and US-based immunotherapy firm is working with advisers on a possible share sale that could raise a few hundred million dollars. A <\/p>\n","protected":false},"author":1,"featured_media":46611,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":{"0":"post-46610","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"_links":{"self":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/46610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/comments?post=46610"}],"version-history":[{"count":0,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/46610\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media\/46611"}],"wp:attachment":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media?parent=46610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/categories?post=46610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/tags?post=46610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}